Ambrilia Biopharma Inc.(TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today that it will be presenting the latest clinical findings on its lead HIV protease inhibitor (PI), PPL-100, a prodrug of PL-100, at the XVI International AIDS Conference (Toronto, Canada).
